Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: Results from a multicentre survey

Canadian Urological Association Journal

Volumn 8, Issue 9-10, 2014, Pages e721-e727

  Cicione, Antonio ^a   Cantiello, Francesco ^a   Ucciero, Giuseppe ^a   Salonia, Andrea ^b   Torella, Marco ^c   De Sio, Marco ^c   Autorino, Riccardo ^c   Carbone, Antonio ^d   Romancik, Martin ^e   Tomaskin, Roman ^f   Damiano, Rocco ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^f Martinska Fakultna Nemocnica   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919921745     PISSN: 19116470     EISSN: 19201214     Source Type: Journal    
DOI: 10.5489/cuaj.1989     Document Type: Article

References (30)

1. Grabe M, Bjerklund-Johansen TE, Botto H, et al. European Urological Association. Guidelines on Urological Infections; 2013. http://www.uroweb.org/gls/pdf/19%20Urological%20infections-LR.pdf. Accessed October 14, 2014.
2. Wagenlehner FM, Weidner W, Naber KG. An update on uncomplicated urinary tract infections in women. Curr Opin Urol 2009;19:368-74. http://dx.doi.org/10.1097/MOU.0b013e32832ae18c
3. Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol 2000;151:1194-205. http://dx.doi.org/10.1093/oxfordjournals.aje. a010170
4. Czaja CA, Stamm WE, Stapleton AE, et al. Prospective cohort study of microbial and inflammatory events immediately preceding Escherichia coli recurrent urinary tract infection in women. J Infect Dis 2009;;200:528-36. http://dx.doi.org/10.1086/600385
5. Albert X, Huertas I, Pereiro II, et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004;CD001209.
6. Arnold LD, Bachmann GA, Rosen R, et al. Assessment of vulvodynia symptoms in a sample of US women: A prevalence survey with a nested case control study. Am J Obstet Gynecol 2007;196:128-6. http://dx.doi.org/10.1016/j.ajog.2006.07.047
7. Arya LA, Northington GM, Asfaw T, et al. Evidence of bladder oversensitivity in the absence of an infection in premenopausal women with a history of recurrent urinary tract infections. BJU Int 2012;110:247-51. http://dx.doi.org/10.1111/j.1464-410X.2011.10766.x
8. Esko JD, Kimata K, Lindahl U. Proteoglycans and Sulfated Glycosaminoglycans. In: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of Glycobiology. 2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2009. Chapter 16. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1900/. Accessed October 14, 2014.
9. Damiano R, Cicione A. The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. Ther Adv Urol 2011;3:223-32. http://dx.doi.org/10.1177/1756287211418723
10. Parsons CL, Greenspan C, Mulholland SG. The primary antibacterial defense mechanism of the bladder. Invest Urol 1975;13:72-8.
11. Parsons CL. New concepts in interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct 1997;8:1-2. http://dx.doi.org/10.1007/BF01920285
12. Lazzeri M, Montorsi F. The therapeutic challenge of "chronic cystitis:" search well, work together, and gain results. Eur Urol 2011;60:78-80. http://dx.doi.org/10.1016/j.eururo.2011.03.039
13. Costantini E, Lazzeri M, Pistolesi D, et al. Morphological changes of bladder mucosa in patients who underwent instillation with combined sodium hyaluronic acid-chondroitin sulphate (Ialuril). Urol Int 2013;91:81-8. http://dx.doi.org/10.1159/000345047
14. De Vita D, Giordano S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: A randomized study. Int Urogynecol J 2012;23:1707-13. http://dx.doi.org/10.1007/s00192-012-1794-z
15. Lipovac M, Kurz C, Reithmayr F, et al. Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynaecol Obstet 2007;96:192-5. http://dx.doi.org/10.1016/j.ijgo.2006.11.025
16. Constantinides C, Manousakas T, Nikolopoulos P, et al. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: A pilot study. BJU Int 2004;93:1262-6. http://dx.doi.org/10.1111/j.1464-410X.2004.04850.x
17. Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: A placebo-controlled randomised trial. Eur Urol 2011;59:645-51. http://dx.doi.org/10.1016/j.eururo.2010.12.039
18. Parsons CL, Dell J, Stanford EJ, et al. Increased prevalence of interstitial cystitis: Previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity. Urology 2002;60:573-8. http://dx.doi.org/10.1016/S0090-4295(02)01829-0
19. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). http://www2.niddk.nih. gov/. Accessed October 14, 2014.
20. Birder LA, de Groat WC. Mechanisms of disease: Involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol 2007;4:46-54. http://dx.doi.org/10.1038/ncpuro0672
21. Parsons CL. The therapeutic role of sulfated polysaccharides in the urinary bladder. Urol Clin North Am 1994;21:93-100.
22. Foxman B, Brown P. Epidemiology of urinary tract infections: Transmission and risk factors, incidence, and costs. Infect Dis Clin North Am 2003;17:227-41. http://dx.doi.org/10.1016/S0891-5520(03)00005-9
23. Nicolle LE. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urol Clin North Am 2008;35:1-12, v. http://dx.doi.org/10.1016/j.ucl.2007.09.004
24. Nicolle LE. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol 2005;16:349-60.
25. Tay H, Parsons CL, Stein PC. Electrophysiologic monitoring of the effects of soluble virulence factors produced by Escherichia coli infection in urine. Urology 1996;48:389-92. http://dx.doi.org/10.1016/S0090-4295(96)00209-9
26. Aslan G, Esen N, Esen AA, et al. Recovery period of the bladder after exposure to soluble virulence factor produced by Escherichia coli. Eur Urol 2001;40:446-50. http://dx.doi.org/10.1159/000049814
27. Kamhi E, Joo EJ, Dordick JS, et al. Glycosaminoglycans in infectious disease. Biol Rev Camb Philos Soc 2013;88:928-43. http://dx.doi.org/10.1111/brv.12034
28. Rouschop KM, Sylva M, Teske GJ, et al. Urothelial CD44 facilitates Escherichia coli infection of the murine urinary tract. J Immunol 2006;177:7225-32. http://dx.doi.org/10.4049/jimmunol.177.10.7225
29. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010;7:653-60. http://dx.doi.org/10.1038/nrurol.2010.190
30. Scott RA, Panitch A. Glycosaminoglycans in biomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2013;5:388-98. http://dx.doi.org/10.1002/wnan.1223